학술논문
142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Subject
Language
ISSN
2590-0188